A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability of C1 Inhibitor (CINRYZE) as a Donor Pre-treatment Strategy in Brain Dead Donors Who Meet a Kidney Donor Risk Index (KDRI) Above 85%

Trial Profile

A Phase I, Single Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Tolerability of C1 Inhibitor (CINRYZE) as a Donor Pre-treatment Strategy in Brain Dead Donors Who Meet a Kidney Donor Risk Index (KDRI) Above 85%

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Complement C1 inhibitor protein (Primary) ; Heparin
  • Indications Renal failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Oct 2017 Last checked against ClinicalTrials.gov record.
    • 28 Sep 2017 Planned End Date changed from 1 Dec 2018 to 1 May 2020.
    • 28 Sep 2017 Planned primary completion date changed from 1 Apr 2018 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top